Analyst Price Targets — ZYME
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 7, 2026 1:15 pm | — | Truist Financial | $31.00 | $26.45 | TheFly | Zymeworks price target raised to $31 from $28 at Truist |
| June 30, 2026 10:24 am | — | Wells Fargo | $37.00 | $24.10 | TheFly | Zymeworks price target raised to $37 from $34 at Wells Fargo |
| June 9, 2026 10:08 am | Gregory Renza | Truist Financial | $28.00 | $23.93 | StreetInsider | Truist Securities Assumes Zymeworks (ZYME) at Buy |
| June 3, 2026 10:52 am | Andrew Berens | H.C. Wainwright | $46.00 | $24.11 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Zymeworks (ZYME) |
| March 9, 2026 12:08 pm | — | Evercore ISI | $48.00 | $24.25 | TheFly | Zymeworks price target raised to $48 from $33 at Evercore ISI |
| December 17, 2025 11:16 am | Asthika Goonewardene | Truist Financial | $40.00 | $25.85 | TheFly | Zymeworks initiated with a Buy at Truist |
| December 12, 2025 10:20 am | — | Wells Fargo | $33.00 | $24.93 | TheFly | Zymeworks upgraded to Overweight from Equal Weight at Wells Fargo |
| December 3, 2025 10:03 am | — | JMP Securities | $32.00 | $25.10 | TheFly | Zymeworks initiated with an Outperform at Citizens JMP |
| November 19, 2025 10:31 am | Eva Verdejo | Wells Fargo | $25.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $25 at Wells Fargo |
| November 19, 2025 9:27 am | Stephen Willey | Stifel Nicolaus | $40.00 | $22.99 | StreetInsider | Zymeworks (ZYME) PT Raised to $40 at Stifel |
Latest News for ZYME
VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026.
Zymeworks Inc. acquires Theravance Biopharma for $929M, pivoting to a hybrid biotech and royalty/cash-flow platform anchored by Yupelri. ZYME gains durable, growing cash flows—$60M annually from Yupelri—with patent protection to 2039, supporting internal R&D and reducing reliance on equity issuance. The acquisition's innovative financing structure ringfences risk, offers immediate accretion, and diversifies revenue…
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zymeworks Inc. (ZYME) M&A Call Transcript
Zymeworks Inc. (NASDAQ:ZYME) said Monday it has agreed to acquire Theravance Biopharma Inc. (NASDAQ:TBPH) in an all-cash transaction valued at about $929 million.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZYME.
U.S. House Trading
No House trades found for ZYME.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.